Luke Walker
Hoofd Techniek/Wetenschap/O&O bij HARPOON THERAPEUTICS, INC.
Vermogen: 861 074 $ op 31-05-2024
Actieve functies van Luke Walker
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
HARPOON THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 03-10-2022 | - |
ZENTALIS PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 29-05-2024 | - |
Independent Dir/Board Member | 29-05-2024 | - |
Loopbaan van Luke Walker
Eerdere bekende functies van Luke Walker
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
CASCADIAN THERAPEUTICS INC (USA) | Hoofd Techniek/Wetenschap/O&O | - | 09-03-2018 |
SEAGEN INC. | Corporate Officer/Principal | - | - |
Opleiding van Luke Walker
University of Oklahoma | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 6 |
Operationeel
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Graduate Degree | 1 |
Sectoraal
Health Technology | 5 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Cascadian Therapeutics LLC
Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
Seagen Inc.
Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
- Beurs
- Insiders
- Luke Walker
- Ervaring